Interferon-α-2b

Interferon-α-2b Reactions 1680, p185 - 2 Dec 2017 Various toxicities: 2 case reports In a retrospective, single-center study of 14 patients, 2 patients [ages not stated, not all sexes stated] were described. Out of whom, one patient developed grade 2 weight loss and other one female developed fever, lymphopenia, anaemia, thoracic pain, hypertension, pulmonary oedema and renal insufficiency along with cardiac arrest during treatment with Both patients had a history of malignant pheochromocytoma/paraganglioma (MPPGL) and they received interferon-α-2b for its treatment. They received SC interferon-α-2b injection 1.5 MU, thrice in a week, 28 day cycle. In one patient interferon-α-2b dose was reduced as the patient developed grade 2 weight loss. The other patient (female) was admitted to the ICU one month after the therapy discontinuation due to fever, lymphopenia and anaemia without any evidence of infectious disease. In addition to this, she complained of hypertension, pulmonary oedema, thoracic pain and renal insufficiency. Thereafter her condition exacerbated and she died because of cardiac arrest. Disease progression was also hypothesised as a cause of death [duration of treatment to reactions onsets not stated; outcome of other ADRs prior to death not stated]. Author comment: "The [interferon]-alpha dose was reduced in four patients: because of asthenia in three patients (one grade 2 and two grade 3) and because of grade 2 weight loss in one patient." "One patient was admitted to the intensive care unit 1 month after [interferon]-alpha discontinuation because of fever, lymphopenia, and anemia with no evidence of infectious disease and normal blood pressure." Hadoux J, et al. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. Hormones and Cancer 8: 330-337, No. 5, Dec 2017. Available from: URL: http://doi.org/10.1007/s12672-017-0303-8 - France 803285003 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Interferon-α-2b

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer-journals/interferon-2b-4tFKNaJszn
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39116-8
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p185 - 2 Dec 2017 Various toxicities: 2 case reports In a retrospective, single-center study of 14 patients, 2 patients [ages not stated, not all sexes stated] were described. Out of whom, one patient developed grade 2 weight loss and other one female developed fever, lymphopenia, anaemia, thoracic pain, hypertension, pulmonary oedema and renal insufficiency along with cardiac arrest during treatment with Both patients had a history of malignant pheochromocytoma/paraganglioma (MPPGL) and they received interferon-α-2b for its treatment. They received SC interferon-α-2b injection 1.5 MU, thrice in a week, 28 day cycle. In one patient interferon-α-2b dose was reduced as the patient developed grade 2 weight loss. The other patient (female) was admitted to the ICU one month after the therapy discontinuation due to fever, lymphopenia and anaemia without any evidence of infectious disease. In addition to this, she complained of hypertension, pulmonary oedema, thoracic pain and renal insufficiency. Thereafter her condition exacerbated and she died because of cardiac arrest. Disease progression was also hypothesised as a cause of death [duration of treatment to reactions onsets not stated; outcome of other ADRs prior to death not stated]. Author comment: "The [interferon]-alpha dose was reduced in four patients: because of asthenia in three patients (one grade 2 and two grade 3) and because of grade 2 weight loss in one patient." "One patient was admitted to the intensive care unit 1 month after [interferon]-alpha discontinuation because of fever, lymphopenia, and anemia with no evidence of infectious disease and normal blood pressure." Hadoux J, et al. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. Hormones and Cancer 8: 330-337, No. 5, Dec 2017. Available from: URL: http://doi.org/10.1007/s12672-017-0303-8 - France 803285003 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off